YahooOctober 20, 2026 at 12:48 PM NY7 Days Ago
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
Spyre Therapeutics' (SYRE) combination therapy approach for inflammatory bowel disease gained furthe
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
